E Fund Management Co., Ltd. Sage Therapeutics, Inc. Transaction History

E Fund Management Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$18.62 - $26.95 $38,394 - $55,570	2,062 Added 12.51%	18,544 $347,000
Q4 2023 Feb 06, 2024	SELL	$17.1 - $22.26 $79,993 - $104,132	-4,678 Reduced 22.11%	16,482 $357,000
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $229,525 - $671,172	13,703 Added 183.76%	21,160 $435,000
Q2 2023 Aug 11, 2023	SELL	$40.65 - $59.54 $79,470 - $116,400	-1,955 Reduced 20.77%	7,457 $351,000
Q1 2023 May 11, 2023	BUY	$37.27 - $46.57 $30,710 - $38,373	824 Added 9.59%	9,412 $395,000
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $88,646 - $120,058	-2,753 Reduced 24.27%	8,588 $328,000
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $14,396 - $19,298	446 Added 4.09%	11,341 $444,000
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $62,222 - $85,895	2,261 Added 26.19%	10,895 $352,000
Q1 2022 May 12, 2022	BUY	$30.71 - $45.71 $211,069 - $314,164	6,873 Added 390.29%	8,634 $286,000
Q1 2021 May 12, 2021	BUY	$70.65 - $96.76 $124,414 - $170,394	1,761 New	1,761 $131,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.